RxDoctor Payments Data

Priscilla Medero Rodriguez, MD

Gastroenterology · Mayaguez, PRNPI 1942564794

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 65.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $3,295 and has fallen 76.1% since, to $788 in 2025.

$6,816in general payments, 2019–2025

Across 97 payments — averaging $70.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • E.r. Squibb & Sons, L.L.C.$779
  • Abbott$240
  • Janssen Scientific Affairs, LLC$213
  • Madrigal Pharmaceuticals$144
  • Johnson & Johnson$128
  • plus $865 from 10 others

What the payments were for

  • Consulting fees$3,15046%
  • Travel & lodging$280%
  • Food & beverage$3,63853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,816 in reported general payments places this provider in the 80th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,022
Medicare patients
18
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf144$23,766
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates225$18,805
SuprepSodium, Potassium,mag Sulfates159$18,803
LinzessLinaclotide15$8,210
CholestyramineCholestyramine (With Sugar)45$2,972
Pantoprazole Sodium323$2,317
Lubiprostone14$1,923
Sucralfate25$1,709
Sodium Chloride0.9 % Sodium Chloride223$1,227
Famotidine142$964
Clarithromycin23$669
Midazolam HclMidazolam Hcl/Pf211$572
Midazolam Hcl198$517
Dicyclomine Hcl25$460
Amoxicillin23$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$4,447$8,21015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →